Evaluation of the Safety of Relaxin in Preeclampsia

• Status: Suspended
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
• Treatments: Methocarbamol

Criteria

Inclusion Criteria:

• Diagnosis of preeclampsia

• Hospital admission for expectant management

Exclusion Criteria:

• Eclampsia or history of seizures

• Vaginal bleeding

• Multifetal gestation

• Requirement for immediate delivery